REG-Norges Bank: Form 8.3 - AbbVie Inc

AbbvieAnnouncement

07/05/2020 10:50

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR
MORE

1.       KEY INFORMATION

 Name of person dealing (Note 1)                                                   Norges Bank                        
 Company dealt in                                                                  AbbVie Inc                         
 Class of relevant security to which the dealings being disclosed relate (Note 2)  US$0.01 common stock US00287Y1091  
 Date of dealing                                                                   06/05/2020                         

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)

                                                         Long            Short            
                                              Number            (%)      Number      (%)  
 (1) Relevant securities                      13,836,342 (0.91%)                          
 (2) Derivatives (other than options)         1,234,300 (0.11%)                           
 (3) Options and agreements to purchase/sell                                              
 Total                                        15,070,642 (1.02%)                          
                                                                                          

(b)        Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)

 Class of relevant security:                        Long       Short            
                                              Number      (%)  Number      (%)  
 (1) Relevant securities                                                        
 (2) Derivatives (other than options)                                           
 (3) Options and agreements to purchase/sell                                    
 Total                                                                          
                                                                                

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

 Purchase/sale  Number of relevant securities  Price per unit (Note 5)  
 Purchase       440,100                        85.4200 USD              

(b)      Derivatives transactions (other than options transactions)

 Product name,  e.g. CFD  Nature of transaction (Note 6)  Number of relevant securities (Note 7)  Price per unit (Note 5)  
 CFD                      Sale                            440,100                                 85.4200 USD              

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

 Product name,  e.g. call option  Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc.  Expiry date  Option money paid/received per unit (Note 5)  
                                                                                                                                                                                                                                                        

(ii)      Exercising

 Product name,  e.g. call option  Number of securities  Exercise price per unit (Note 5)  
                                                                                          

(d)          Other dealings (including transactions in respect of new
securities) (Note 4)

 Nature of transaction (Note 8)  Details  Price per unit  (if applicable) (Note 5)  
                                                                                    

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting
rights or future acquisition or disposal of any relevant securities to which
any derivative referred to on this form is referenced. If none, this should be
stated.

Is a Supplemental Form 8 attached? (Note
9)                                          
 /NO

 Date of disclosure                                                07/05/2020         
 Contact name                                                      Philippe Chiaroni  
 Telephone number                                                  +47 2407 3297      
 If a connected EFM, name of offeree/offeror with which connected                     
 If a connected EFM, state nature of connection (Note 10)                             



Copyright (c) 2020 PR Newswire Association,LLC. All Rights Reserved